Apellis (APLS) CTO Nicholson Nur sells 2,203 shares for tax withholding

Rhea-AI Filing Summary

Apellis Pharmaceuticals, Inc. insider transaction: Chief Technical Officer Nicholson Nur reported a sale of 2,203 shares of Apellis common stock on January 20, 2026, at a price of $19.7929 per share. According to the footnote, these shares were sold to cover tax withholding related to Restricted Stock Units that were released on January 16, 2026, rather than as an open-market discretionary sale. After this transaction, Nur beneficially owned 78,843 shares of Apellis common stock in direct ownership.

Insider Trade Summary

Net Seller: 2,203 shares ($43,604)

Net Sell 1 txn

Insider Nicholson Nur

Role Chief Technical Officer

Sold 2,203 shs ($44K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,203	$19.7929	$44K

Holdings After Transaction: Common Stock — 78,843 shares (Direct)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nicholson Nur

(Last) (First) (Middle)

C/O APELLIS PHARMACEUTICALS, INC.

100 FIFTH AVENUE, 3RD FLOOR

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Apellis Pharmaceuticals, Inc. [ APLS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/20/2026		S(1)		2,203	D	$19.7929	78,843	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This represents shares sold to cover tax withholding on the Restricted Stock Units released on January 16, 2026.

	/s/ David Watson, attorney-in-fact for Nur Nicholson	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Apellis Pharmaceuticals (APLS) report for Nicholson Nur?

Apellis Pharmaceuticals reported that Chief Technical Officer Nicholson Nur sold 2,203 shares of common stock on January 20, 2026 at $19.7929 per share.

Why were Nicholson Nur’s Apellis (APLS) shares sold in this Form 4 filing?

The filing explains that the 2,203 shares were sold to cover tax withholding on Restricted Stock Units that were released on January 16, 2026.

How many Apellis (APLS) shares does Nicholson Nur hold after this transaction?

After the reported sale, Nicholson Nur beneficially owned 78,843 shares of Apellis common stock in direct ownership.

What is Nicholson Nur’s role at Apellis Pharmaceuticals (APLS)?

Nicholson Nur is identified in the filing as an officer of Apellis Pharmaceuticals, serving as Chief Technical Officer.

Was the Apellis (APLS) insider transaction part of a derivative or non-derivative security?

The reported transaction involved non-derivative securities, specifically Apellis common stock, as shown in Table I of the filing.